Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + fluorouracil + tamoxifen

Development stage: Phase 3
Lead developer: Baxter
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy and hormonal therapy regimen consisting of three cytotoxic agents (cyclophosphamide, doxorubicin, and fluorouracil) plus the selective estrogen receptor modulator tamoxifen. This regimen is primarily used in the treatment of breast cancer, particularly in hormone receptor-positive disease. Each component works through different mechanisms to target cancer cells, with cyclophosphamide damaging DNA, doxorubicin interfering with DNA production and repair, fluorouracil preventing DNA synthesis, and tamoxifen blocking estrogen effects in breast tissue.

Other names: CAFTCAUT

Targets

DNAER (Estrogen receptor)TS (Thymidylate synthase)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + fluorouracil + tamoxifen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + tamoxifen.